Kanaph Therapeutics Inc.

₩8,900As of Sun 8 Nov 2026, 12:00 UTC

KOSDAQ:0082N0Healthcare

Country South Korea

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE (29.02%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap ₩116.5B

ROIC (36.66%)

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₩9,610

—

7.98%

—

TTM

FYE 31 Dec KRW

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

3.789

Revenue₩B

—

5.250

0.348

4.252

5.561

3.433

1.93%

—

Revenue growth%

—

(93.36)

1120.15

30.79

(38.26)

30.79

—

Gross margin%

—

100.00

—

(353.99)

Operating margin%

—

(225.41)

(3007.76)

(111.08)

(76.84)

(100.00)

(168.25)

—

(332.32)

Net margin%

—

(55.66)

(3612.02)

(664.96)

(639.50)

(100.00)

(652.23)

—

P/E ratio (avg)x

—

EV/EBITx

—

(10.27)

FCF yield (avg)%

—

(9.01)

—

(320.89)

FCF margin%

—

(145.31)

(2818.16)

(77.62)

(130.28)

(100.00)

(137.79)

—

0.966

FCF / Net incomex

—

2.611

0.780

0.117

0.204

—

0.492

—

(36.66)

ROIC%

—

(9.38)

—

(29.02)

Return on equity%

—

(7.99)

—

(27.50)

Return on assets%

—

(41.68)

(62.25)

(141.19)

(229.99)

(7.64)

(101.72)

—

(946.15)

EPS₩

—

(1,667)

(2,963)

(6,605)

(8,308)

(802.01)

—

EPS growth%

—

(77.74)

(122.92)

(25.78)

90.35

(77.74)

—

3,261

Bookvalue per sh₩

—

(23,481)

(11,803)

(18,150)

2,892

9,936

—

(913.60)

FCF per share₩

—

(4,352)

(2,312)

(770.96)

(1,692)

(802.01)

—

Dividend per sh₩

—

Div yield (avg)%

—

Payout ratio%

—

4.280

Shares (diluted)M

—

1.753

4.248

4.280

—

◌4.280

56.27%

—

Buyback yield%

—

(142.34)

(0.77)

—

(71.55)

—

0.020

D/E ratiox

—

(0.010)

—

0.025

0.020

—

37.74

Enterprise value₩B

—

32.15

—

LT debt₩M

—

Peers (US$85.02M)

Cap (US$)

AriBioLab Co.,Ltd.

88.81M

—

Bio Solution Co.,Ltd.

88.47M

132.0x

Y-Biologics, Inc.

83.39M

—

Novogenia AG

84.89M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

—

(2.154)

Own earn%

—

Sh yield%

—

(71.55)

Owners

Insiders/Inst%

23.29

7.62

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

2/3

EPS growth years

0/3

Dividend streakyrs

Op margin range%

−3008–−77

$1 testx

—

Incr. ROIC%

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

₩5.561B

1.93%

1.00×

Operating expenses

₩9.833B

(16.82%)

0.54×

Asset mix

Trend

Other

91.27%

Cash and investments

7.88%

Goodwill & intangibles

0.86%

Reinvestment returns

No breakdown available